■本研究旨在确定复发性或转移性头颈部鳞状细胞癌(HNSCC)患者的潜在生物标志物,并进一步探讨CDKN2A突变的预后意义。特别是在接受免疫治疗的子集内。
■在这项回顾性单中心研究中,我们评估了基础医学(FM)在2019年1月1日至2021年12月31日期间复发或转移性HNSCC患者的下一代测序(NGS)数据.根据CDKN2A功能丧失(LOF)和野生型(WT)分类对患者进行分层,对免疫疗法进行了重点亚组分析。
■该研究涵盖77名患者,其中62人接受了免疫疗法。中位随访时间为22.6个月。对于CDKN2ALOF组,中位总生存期(OS)为16.5个月,与CDKN2AWT组的30.0个月相比(P=0.014)。值得注意的是,女性(风险比[HR]=4.526,95%置信区间[CI]:1.934~10.180,P=0.0003)和CDKN2ALOF(HR=2.311,95%CI:1.156~4.748,P=0.019)是复发或转移性HNSCC患者死亡的独立危险因素.在免疫疗法子集内,CDKN2ALOF组的中位OS为11.7个月,CDKN2AWT组为22.5个月(P=0.017)。Further,女性(HR=4.022,95%CI:1.417-10.710,P=0.006),CDKN2ALOF(HR=4.389,95%CI:1.782-11.460,P=0.002),在接受免疫治疗的复发性或转移性HNSCC患者中,合并阳性评分低于1(HR=17.20,95%CI:4.134-79.550,P<0.0001)被确定为死亡率的显著预测因子。
■显示为CDKN2A基因LOF的改变是HNSCC患者不良生存结局的有力指标,包括接受免疫治疗的子集。
UNASSIGNED: This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy.
UNASSIGNED: In this retrospective single-center study, we evaluated the next-generation sequencing (NGS) data from Foundation Medicine (FM) for patients with recurrent or metastatic HNSCC between January 1, 2019, and December 31, 2021. Patients were stratified based on CDKN2A loss-of-function (LOF) versus wild-type (WT) categorizations, with a focused subgroup analysis on those administered immunotherapy.
UNASSIGNED: The study encompassed 77 patients, of which 62 had undergone immunotherapy. The median duration of follow-up was 22.6 months. For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group (P=0.014). Notably, female gender (hazard ratio [HR]=4.526, 95% confidence interval [CI]: 1.934-10.180, P=0.0003) and CDKN2A LOF (HR=2.311, 95% CI: 1.156-4.748, P=0.019) emerged as independent risk factors for mortality in patients with recurrent or metastatic HNSCC. Within the immunotherapy subset, the median OS was 11.7 months for the CDKN2A LOF group, and 22.5 months for the CDKN2A WT group (P=0.017). Further, the female gender (HR=4.022, 95% CI: 1.417-10.710, P=0.006), CDKN2A LOF (HR=4.389, 95% CI: 1.782-11.460, P=0.002), and a combined positive score below 1 (HR=17.20, 95% CI: 4.134-79.550, P<0.0001) were identified as significant predictors of mortality among patients with recurrent or metastatic HNSCC receiving immunotherapy.
UNASSIGNED: Alterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy.